- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Jefferies initiates Sera Prognostics stock with Buy rating on preterm birth test | 1 | Investing.com | ||
| Mo | Jefferies stuft Sera Prognostics mit "Buy" ein - Frühgeburtentest als Kurstreiber | 3 | Investing.com Deutsch | ||
| 14.11. | Sera Prognostics outlines accelerated Medicaid pilot expansion to 13 states as commercialization momentum builds | 1 | Seeking Alpha | ||
| 13.11. | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2025 Financial Results | 713 | PR Newswire | SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 13.11. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.10. | Sera Prognostics Appoints Tiffany Inglis As CMO | - | RTTNews | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 01.10. | Sera Prognostics appoints Dr. Tiffany Inglis as chief medical officer | 1 | Investing.com | ||
| 01.10. | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 110 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 05.09. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.09. | Sera Prognostics forciert Kommerzialisierung des PreTRM-Tests | 1 | Investing.com Deutsch | ||
| 21.08. | Sera Prognostics übertrifft Gewinnprognose - Aktie steigt trotz schwachem Umsatz | 3 | Investing.com Deutsch | ||
| 07.08. | Sera Prognostics outlines European expansion and new commercial hires while targeting PreTRM Test reimbursement pilots | 1 | Seeking Alpha | ||
| 06.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 94 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 08.05. | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 238 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 340 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 239 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,505 | -2,59 % | NanoRepro: Zwei Aufsichtsräte treten zurück | Nachdem NanoRepro am Freitag das Verlangen der HWT invest Aktiengesellschaft auf Einberufung einer außerordentlichen Hauptversammlung publik gemacht hat, sind nun zwei Aufsichtsräte zurückgetreten.... ► Artikel lesen | |
| OCUGEN | 1,178 | -0,08 % | Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit | ||
| VIKING THERAPEUTICS | 31,000 | +0,68 % | This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street | ||
| COSCIENS BIOPHARMA | 1,760 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | - | - | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| BIOCRYST PHARMACEUTICALS | 6,384 | -1,24 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| VAXART | 0,281 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| IBIO | 1,640 | +4,46 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update |
Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,190 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,304 | +2,09 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| CARDIFF ONCOLOGY | 2,040 | 0,00 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| MANNKIND | 4,983 | -1,52 % | MannKind: Leerink hebt Kursziel wegen Tyvaso-DPI-Lizenzeinnahmen auf 9 US-Dollar an | ||
| ALDEYRA | 2,800 | -17,43 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| TRAWS PHARMA | 2,250 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 | Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,148 | -3,37 % | Coherus Oncology, Inc.: Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer | - Responsible for Corporate Development, Investor Relations, Government Affairs - REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that... ► Artikel lesen |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,380 Euro und damit -3,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.